Email wenjiach@nus.edu.sg

Every year, substantial health losses and avoidable costs arise from poorly targeted care for patients with chronic diseases. Heterogeneity in phenotypes and endotypes, multimorbidity, and health inequalities poses great challenges in chronic disease management.

Dr Chen and her team address this complexity through a focus on precision medicine and AI-empowered personalised care. Her work integrates health technology assessment, economic evaluation, real-world evidence, and data science to ensure that emerging technologies are clinically useful, cost-effective, and equitable.

• NUS Saw Swee Hock School of Public Health

• Precision medicine and clinical AI economics
• Chronic respiratory medicine: economic burden, value-based care, environmental impact
• Health technology assessment, pricing and reimbursement models

• Health services use, costs and health outcomes
• Health technology assessment
• Real-world big data methods
• Applied longitudinal analysis

• PhD in Health Economics and Outcomes (2016), University of British Columbia, Canada
• MPH in Health Economics (2010), University of Pennsylvania, US
• MSc in Neuroscience (2008), University of Iowa, US
• BSc in Biotechnology (2005), Sun Yat-Sen University, China

• HPHSR Clinician Scientist Award (Investigator)

• Post-doctoral fellow, University of British Columbia, Canada (2018 – 2020)
• Post-doctoral fellow, University of Toronto, Canada (2017 – 2018)
• Research fellow, Merck & Co., Inc, US (2010 – 2012)

• Research Fellow, Observational & Pragmatic Research Institute, Singapore (2022 – present)

• Zhang Y, Lin Z, Teerawattananon Y, […] Chen W. The value for money of artificial intelligence-empowered precision medicine: a systematic review and regression analysis. npj Digit. Med. (2025). https://doi.org/10.1038/s41746-025-02259-w
• Lim LHM, Juang YR, Chotirmall SH, […] Chen W. Economic burden of asthma multimorbidity in Singapore: Shadow costs of steroid use. World Allergy Organ J. 2025 Nov 27;18(12):101146.
• Chen W, Butani D, Wang Y, […] Teerawattananon Y. Development of the PICCOTEAM Reference Case for Economic Evaluation of Precision Medicine. Int J Health Policy Manag. 2025 Sep 8;14:8756.
• Yadav CP, Chakraborty A, Price DB, […] Chen W. Prediction Pathway for Severe Asthma Exacerbations: A Bayesian Network Analysis. Chest. 2025 Aug;168(2):301-316.
• Chen W, Tran TN, Townend J, […] Price DB; ISAR SOLAR I Working Group. Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data. J Allergy Clin Immunol Pract. 2025 Aug;13(8):2033-2048.
• Chen W, Wang Y, Zemlyanska Y, Butani D, Wong NCB, Virabhak S, Matchar DB, Teerawattananon Y. Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access: A Comprehensive Review of Approaches and Challenges. Value Health. 2023 Sep;26(9):1425-1434.
• Chen W, Tran TN, […] Price DB. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2023 Sep;11(9):2732-2747.
• Chen W, Reddel HK, FitzGerald JM, Beasley R, Janson C, Sadatsafavi M. Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials. Respir Res. 2023 May 2;24(1):120.
• Chen W, Wong NCB, Wang Y, Zemlyanska Y, Butani D, Virabhak S, Matchar DB, Prapinvanich T, Teerawattananon Y. Mapping the value for money of precision medicine: a systematic literature review and meta-analysis. Front Public Health. 2023 Nov 24;11:1151504.
• Chen W, Sin DD, FitzGerald JM, Safari A, Adibi A, Sadatsafavi M. An Individualized Prediction Model for Long-term Lung Function Trajectory and Risk of COPD in the General Population. Chest.2020 Mar;157(3):547-557.
• Chen W, Safari A, FitzGerald JM, Sin DD, Tavakoli H, Sadatsafavi M. Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study. Thorax. 2019 Dec;74(12):1113-1119.
• Chen W, FitzGerald JM, Sin DD, Sadatsafavi M; Canadian Respiratory Research Network. Excess economic burden of comorbidities in COPD: a 15-year population-based study. Eur Respir J. 2017 Jul 27;50(1):1700393.
• Chen W, Marra CA, Lynd LD, FitzGerald JM, Zafari Z, Sadatsafavi M. The natural history of severe asthma and influences of early risk factors: a population-based cohort study. Thorax. 2016 Mar;71(3):267-75.
• Chen W, Thomas J, Sadatsafavi M, Fitzgerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respiratory Medicine. 2015; 3(8):631-9.

• 联合早报 | 研究：住院率居高不下 哮喘患者须提高意识控制病情. 2024年4月5日.
• Straits Times | Lose my breath: Increase in asthma hospitalisation rate in Singapore forecast, heat can be a trigger. May 28, 2024.